Granules India Submits Paragraph IV ANDA for Ruxolitinib Extended-Release Tablets
Granules India Ltd 路 Press Release 路 07 Oct 2026, 6:10 pm
Granules India Submits Paragraph IV ANDA for Ruxolitinib Extended-Release Tablets Granules India Limited announced on 7th Oct'26 that it has submitted a Paragraph IV certification with its Abbreviated New Drug Application (ANDA) for generic Ruxolitinib Extended-Release Tablets to the US FDA. Based on filing status and timing, the company believes it is eligible for first-to-file status, which, upon FDA confirmation and statutory approvals, could provide 180 days of generic drug marketing exclusivity under US law. The ANDA, exclusivity status, and commercialization prospects remain under regulatory review.
Original exchange filing (PDF)
More announcements from Granules India Ltd
- Schedule of Investor Meet 路 11 Nov 2026
- Change in Corporate Office Address of Registrar and Share Transfer Agent (RTA) 路 06 Nov 2026
- Transcript of the Earnings Conference Call for Q2 and the half year of FY27 路 06 Nov 2026
- Audio recording of the Earnings Conference call for Q2 and the half -year of FY27 路 03 Nov 2026
- Monitoring Agency Report for the quarter ended on September 30, 2026 路 02 Nov 2026
- Investor Presentation to Analysts/Investors 路 02 Nov 2026
- Press Release 路 02 Nov 2026
- Unaudited financial results for the second quarter and half year ended on September 30,2026 路 02 Nov 2026
